ARS Pharmaceuticals, Inc. (SPRY)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore 2 and qualitativeScore 2 both fall below the required floor of 3 (negative stockholders' equity, ~$46M quarterly burn, $25M minimum-liquidity covenant), so no bullish entry is permitted; neither entry type qualifies anyway — a pullback limit is countertrend (price 3.595 below SMA50 4.19 with MACD -0.35), and a breakout stop above the nearest settled level 3.79 gives R/R 0.48 (< 1.0).
Company overview
ARS Pharmaceuticals, Inc. develops ARS-1, an intranasal epinephrine spray for allergic reactions, including Neffy, a low-dose version. Founded in 2015, it is based in San Diego, California.
Fundamental
weakARS Pharmaceuticals faces high risk due to negative equity, cash burn, and liquidity constraints.
Heavily cash-burning, single-product commercial biotech: neffy revenue is ramping (TTM $122.1M; product revenue +49% in the first nine months of 2026) and third-quarter costs were cut hard, but losses, negative stockholders' equity and roughly three to four quarters of burn coverage against a $25M minimum-liquidity covenant leave the equity highly speculative. High risk; watchlist until the breakeven path is demonstrated or funded.
Sentiment
weakSentiment remains flat following a Q3 miss and broker downgrades, with no positive catalysts in sight.
The dominant driver is a bearish Q3 2026 print (announced, 2026-11-05) — EPS missed by roughly $0.06 and revenue came in below consensus, and the post-print sell-side reaction was unambiguously negative (Raymond James cut to Outperform from Strong Buy with the target trimmed to $17; Cantor Fitzgerald maintained but lowered to $20) — sitting on top of an unresolved securities class-action overhang. The trailing-14-day aggregate is flat (+0.01 across 10 scored items) and the 30-to-90-day baseline has no measured polarity (no scorable coverage; item-level tilt mixed-to-negative), so no positive delta exists; the Red-Flag Screen is clean and no cap was applied.
Technical
weakThe stock shows a short-term bounce but remains in a primary downtrend.
Chart score 2. SPRY is still in a well-established primary downtrend: price 3.595 sits below SMA20 3.64, SMA50 4.19 and SMA200 7.13 (roughly -50% from the 13.15 year high), and ADX14 30.03 with price below every long moving average is a strong DOWN-trend read rather than a bullish one. The last two sessions (+12.5% on 2026-11-09, +14.1% on 2026-11-10 off the 2.44 capitulation low) are an oversold bounce, not a trend change: RSI14 has repaired from 20.68 to 47.71 and the MACD histogram has narrowed from -0.10 to -0.01, but MACD line -0.35 remains below signal -0.34 and below zero, and the bounce has only just reached the SMA20 from underneath. What keeps this from a 1 is that the short-term stack has been reclaimed (EMA9 3.26, WMA9 3.11, DEMA14 3.04, TEMA14 3.02 all below price) and today's VWAP 3.43 sits under the tape — so the read is 'bounce-only inside a broken trend', which maps to 2, not 3. The tradable verdict is Do Nothing regardless, because fundamentalScore 2 and qualitativeScore 2 both fail the ≥3 override floor.
You’re looking at 2026-11-10 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

